CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical ...
It’s been a long road to market for Aveo Oncology’s Fotivda, known for years as tivozanib, but the drug finally scored its FDA nod. On Wednesday, after numerous regulatory setbacks, Fotivda nabbed an ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Investors had accused the Cambridge biotech and the former ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results